(BFM Bourse) – In receivership since November, the Montpellier commercial court ordered the judicial liquidation of the Hérault biotech. The Deinove share will soon be delisted.
Curtain down for Deinove. The Montpellier Commercial Court ordered the judicial liquidation of the biotech company headed by Alexis Rideau on Monday January 23. The company had been in receivership since November 7.
The tricolor biotech, in lack of financing, was not the subject of any takeover offer, before the expiry of the deadline for submitting offers to the judicial administrator which had been set for January 9, 2023, at 12.
Founded in 2006, Deinove originally produced bioethanol from bacteria. Four years later, the company went public on Alternext – which later became Euronext Growth – in order to finance the development of its process using deinococcus, these ultra-resistant bacteria capable of resurrecting in a few hours.
The bankruptcy of its partner Abengoa in biofuels in 2016 forced the company to make a strategic shift. Deinove was forced to abandon the manufacture of biofuel and invested in the pharmaceutical and cosmetics sectors for which it manufactured biosourced active ingredients.
The company had asked Euronext to suspend the listing of its share on January 11 at a price of 0.06 euro. The exchanges will be suspended until the end of “the procedure for delisting Deinove shares which should take place shortly after consultation with Euronext Paris” recalls Deinove.
In the event that the compulsory liquidation does not give rise to the distribution of a bonus to the shareholders, the Hérault company would then inform its shareholders that their shares are worthless.
Sabrina Sadgui – ©2023 BFM Bourse
Are you following this action?
Receive all the information about DEINOVE in real time: